Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies
July 22nd 2022Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
Read More